Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Trial to Evaluate BOLD-100 in COVID-19

X
Trial Profile

A Phase 2 Trial to Evaluate BOLD-100 in COVID-19

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BOLD 100 (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Sponsors Bold Therapeutics
  • Most Recent Events

    • 06 Jan 2021 According to a Bold Therapeutics media release, company is selected to receive advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support BOLD-100, as a novel antiviral therapy for SARS-CoV-2 (aka COVID-19). The funding will be utilized to support preparations for clinical trials
    • 18 Dec 2020 According to a Bold Therapeutics media release, the company expects to initiate this trial in mid-2021.
    • 20 Aug 2020 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top